Ikena Total Liab vs Net Invested Capital Analysis

IKNA Stock

USD 1.71 0.01 0.58%

Ikena Oncology financial indicator trend analysis is infinitely more than just investigating Ikena Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ikena Oncology is a good investment. Please check the relationship between Ikena Oncology Total Liab and its Net Invested Capital accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

Total Liab vs Net Invested Capital

Total Liab vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ikena Oncology Total Liab account and Net Invested Capital. At this time, the significance of the direction appears to have pay attention.

The correlation between Ikena Oncology's Total Liab and Net Invested Capital is -0.92. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Ikena Oncology, assuming nothing else is changed. The correlation between historical values of Ikena Oncology's Total Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Ikena Oncology are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Total Liab i.e., Ikena Oncology's Total Liab and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Ikena Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ikena Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.At present, Ikena Oncology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.86, whereas Selling General Administrative is forecasted to decline to about 17.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	65.1M	86.5M	83.6M	70.7M
Cost Of Revenue	47.1M	2.0M	1.0M	969K

Total Operating Expenses Cost Of Revenue

Ikena Oncology fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Current Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital
Other Current Liab		0.72	0.26	0.8	-0.91	0.02	0.65	0.91	0.65	0.97	0.9	-0.96	0.82	0.91	-0.78	-0.77	0.47	0.94	0.98	0.89	0.9	0.61	-0.6	0.91	-0.6	0.82
Total Current Liabilities	0.72		0.76	0.51	-0.61	-0.43	0.49	0.9	0.07	0.61	0.79	-0.82	0.56	0.63	-0.42	-0.8	0.62	0.61	0.65	0.79	0.55	0.27	-0.27	0.56	-0.26	0.56
Other Liab	0.26	0.76		-0.08	-0.17	-0.81	0.32	0.45	-0.44	0.16	0.24	-0.35	-0.02	0.06	-0.03	-0.34	0.28	0.08	0.17	0.25	0.03	0.03	0.24	0.03	0.24	-0.02
Net Tangible Assets	0.8	0.51	-0.08		-0.86	0.12	0.57	0.78	0.85	0.85	0.85	-0.73	1.0	0.96	-0.82	-0.65	0.43	0.95	0.88	0.83	0.94	0.66	-0.93	0.96	-0.93	1.0
Retained Earnings	-0.91	-0.61	-0.17	-0.86		0.05	-0.86	-0.8	-0.69	-0.91	-0.82	0.84	-0.88	-0.87	0.97	0.63	-0.3	-0.92	-0.95	-0.8	-0.87	-0.85	0.74	-0.91	0.75	-0.88
Accounts Payable	0.02	-0.43	-0.81	0.12	0.05		-0.22	-0.12	0.37	0.0	0.1	-0.05	0.08	0.07	0.02	-0.12	0.16	0.05	0.03	0.1	0.05	-0.03	-0.05	0.05	-0.05	0.08
Other Current Assets	0.65	0.49	0.32	0.57	-0.86	-0.22		0.59	0.38	0.63	0.57	-0.62	0.59	0.54	-0.89	-0.47	0.18	0.61	0.7	0.56	0.54	0.94	-0.45	0.61	-0.48	0.59
Total Current Assets	0.91	0.9	0.45	0.78	-0.8	-0.12	0.59		0.48	0.86	0.97	-0.95	0.81	0.88	-0.64	-0.92	0.73	0.87	0.89	0.97	0.83	0.49	-0.53	0.83	-0.52	0.81
Common Stock	0.65	0.07	-0.44	0.85	-0.69	0.37	0.38	0.48		0.78	0.6	-0.49	0.83	0.81	-0.71	-0.37	0.21	0.83	0.76	0.57	0.87	0.6	-0.86	0.86	-0.86	0.83
Property Plant Equipment	0.97	0.61	0.16	0.85	-0.91	0.0	0.63	0.86	0.78		0.85	-0.87	0.86	0.94	-0.81	-0.68	0.4	0.97	0.99	0.83	0.96	0.64	-0.71	0.96	-0.71	0.86
Total Assets	0.9	0.79	0.24	0.85	-0.82	0.1	0.57	0.97	0.6	0.85		-0.94	0.87	0.91	-0.67	-0.95	0.76	0.89	0.9	1.0	0.86	0.53	-0.6	0.86	-0.6	0.87
Short Long Term Debt Total	-0.96	-0.82	-0.35	-0.73	0.84	-0.05	-0.62	-0.95	-0.49	-0.87	-0.94		-0.75	-0.85	0.68	0.89	-0.62	-0.85	-0.91	-0.94	-0.8	-0.52	0.45	-0.81	0.45	-0.75
Total Stockholder Equity	0.82	0.56	-0.02	1.0	-0.88	0.08	0.59	0.81	0.83	0.86	0.87	-0.75		0.97	-0.83	-0.68	0.45	0.96	0.9	0.85	0.95	0.66	-0.92	0.96	-0.92	1.0
Property Plant And Equipment Net	0.91	0.63	0.06	0.96	-0.87	0.07	0.54	0.88	0.81	0.94	0.91	-0.85	0.97		-0.78	-0.73	0.5	0.99	0.95	0.9	0.99	0.58	-0.84	0.98	-0.84	0.97
Current Deferred Revenue	-0.78	-0.42	-0.03	-0.82	0.97	0.02	-0.89	-0.64	-0.71	-0.81	-0.67	0.68	-0.83	-0.78		0.45	-0.12	-0.83	-0.85	-0.65	-0.79	-0.93	0.77	-0.84	0.79	-0.83
Net Debt	-0.77	-0.8	-0.34	-0.65	0.63	-0.12	-0.47	-0.92	-0.37	-0.68	-0.95	0.89	-0.68	-0.73	0.45		-0.91	-0.71	-0.75	-0.96	-0.67	-0.38	0.34	-0.67	0.33	-0.68
Cash	0.47	0.62	0.28	0.43	-0.3	0.16	0.18	0.73	0.21	0.4	0.76	-0.62	0.45	0.5	-0.12	-0.91		0.44	0.46	0.78	0.44	0.12	-0.13	0.42	-0.12	0.45
Non Current Assets Total	0.94	0.61	0.08	0.95	-0.92	0.05	0.61	0.87	0.83	0.97	0.89	-0.85	0.96	0.99	-0.83	-0.71	0.44		0.98	0.88	0.99	0.66	-0.83	1.0	-0.83	0.96
Non Currrent Assets Other	0.98	0.65	0.17	0.88	-0.95	0.03	0.7	0.89	0.76	0.99	0.9	-0.91	0.9	0.95	-0.85	-0.75	0.46	0.98		0.89	0.96	0.71	-0.72	0.97	-0.72	0.9
Cash And Short Term Investments	0.89	0.79	0.25	0.83	-0.8	0.1	0.56	0.97	0.57	0.83	1.0	-0.94	0.85	0.9	-0.65	-0.96	0.78	0.88	0.89		0.84	0.51	-0.57	0.84	-0.57	0.85
Common Stock Total Equity	0.9	0.55	0.03	0.94	-0.87	0.05	0.54	0.83	0.87	0.96	0.86	-0.8	0.95	0.99	-0.79	-0.67	0.44	0.99	0.96	0.84		0.62	-0.85	1.0	-0.85	0.95
Common Stock Shares Outstanding	0.61	0.27	0.03	0.66	-0.85	-0.03	0.94	0.49	0.6	0.64	0.53	-0.52	0.66	0.58	-0.93	-0.38	0.12	0.66	0.71	0.51	0.62		-0.6	0.68	-0.63	0.66
Non Current Liabilities Total	-0.6	-0.27	0.24	-0.93	0.74	-0.05	-0.45	-0.53	-0.86	-0.71	-0.6	0.45	-0.92	-0.84	0.77	0.34	-0.13	-0.83	-0.72	-0.57	-0.85	-0.6		-0.86	1.0	-0.92
Other Stockholder Equity	0.91	0.56	0.03	0.96	-0.91	0.05	0.61	0.83	0.86	0.96	0.86	-0.81	0.96	0.98	-0.84	-0.67	0.42	1.0	0.97	0.84	1.0	0.68	-0.86		-0.86	0.96
Total Liab	-0.6	-0.26	0.24	-0.93	0.75	-0.05	-0.48	-0.52	-0.86	-0.71	-0.6	0.45	-0.92	-0.84	0.79	0.33	-0.12	-0.83	-0.72	-0.57	-0.85	-0.63	1.0	-0.86		-0.92
Net Invested Capital	0.82	0.56	-0.02	1.0	-0.88	0.08	0.59	0.81	0.83	0.86	0.87	-0.75	1.0	0.97	-0.83	-0.68	0.45	0.96	0.9	0.85	0.95	0.66	-0.92	0.96	-0.92

Click cells to compare fundamentals

Ikena Oncology Account Relationship Matchups

Ikena Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	121K	5.4M	5.9M	8.3M	8.6M	5.2M
Total Current Liabilities	24.3M	28.3M	27.2M	21.5M	14.2M	21.9M
Net Tangible Assets	(61.5M)	(101.0M)	207.9M	147.0M	169.0M	177.5M
Retained Earnings	(67.1M)	(111.3M)	(145.5M)	(214.2M)	(282.4M)	(268.3M)
Accounts Payable	935K	2.1M	2.4M	2.1M	2.1M	2.2M
Other Current Assets	1.3M	1.6M	629K	964K	3.2M	3.4M
Total Current Assets	85.2M	166.0M	236.5M	160.0M	178.7M	155.2M
Property Plant Equipment	769K	1.6M	2.4M	3.2M	3.7M	1.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AVAV	AeroVironment
ELVN	Enliven Therapeutics
NFLX	Netflix

When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:

How To Invest In Ikena

Details

Is Ikena Stock a good investment?

Details

What is Ikena Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.42)

Revenue Per Share

0.039

Quarterly Revenue Growth

(0.88)

Return On Assets

(0.27)

Return On Equity

(0.45)

The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ikena Total Liab vs Net Invested Capital Analysis

Total Liab vs Net Invested Capital

Total Liab vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Total Liab

Net Invested Capital

Ikena Oncology fundamental ratios Correlations

Ikena Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ikena Oncology fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Net Tangible Assets
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Non Current Assets Total
Other Stockholder Equity	+ 1.0	Common Stock Total Equity

Cash And Short Term Investments	- 0.96	Net Debt
Short Long Term Debt Total	- 0.96	Other Current Liab
Net Debt	- 0.95	Total Assets
Short Long Term Debt Total	- 0.95	Total Current Assets
Non Currrent Assets Other	- 0.95	Retained Earnings
Cash And Short Term Investments	- 0.94	Short Long Term Debt Total